Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.
Vaccine
; 40(15): 2342-2351, 2022 04 01.
Article
in English
| MEDLINE | ID: covidwho-1740250
ABSTRACT
An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Rhabdoviridae
/
Viral Vaccines
/
COVID-19
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Animals
Language:
English
Journal:
Vaccine
Year:
2022
Document Type:
Article
Affiliation country:
J.vaccine.2021.12.063
Similar
MEDLINE
...
LILACS
LIS